Every 10-Q that PepGen Inc. (PEPG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PEPG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PEPG filings page.
PepGen Inc. is a clinical-stage biotech focused on its lead oligonucleotide candidate PGN‑EDODM1 for DM1, after discontinuing its DMD program PGN‑EDO51 in May 2025. For the quarter ended June 30, 2026, it reported a net loss of $17.8 million, improved from $23.1 million a year earlier, as research and development spending declined to $12.5 million and general and administrative expenses were $6.4 million.
For the first six months of 2026, PepGen’s net loss was $35.6 million versus $53.3 million in 2025, driven mainly by lower manufacturing and clinical costs following the DMD wind‑down. The company held $117.2 million in cash, cash equivalents and marketable securities as of June 30, 2026, and believes this will fund currently planned operations into the fourth quarter of 2027. PGN‑EDODM1 has shown dose‑dependent splicing correction up to 53.7% in a Phase 1 study, and a Phase 2 FREEDOM2 trial is progressing with 10 mg/kg data expected in November 2026 and 12.5 mg/kg data in the first half of 2027. PepGen remains highly dependent on the success of PGN‑EDODM1 and anticipates needing substantial additional capital over time as it advances development.
PepGen Inc. reported another quarterly loss as it advances its neuromuscular disease pipeline. For the three months ended March 31, 2026, net loss was $17.8 million, improving from $30.2 million a year earlier, as research and development spending declined.
Research and development expense fell to $13.0 million from $25.4 million, mainly due to lower manufacturing and personnel costs following discontinuation of its DMD program, while general and administrative expense was flat at $5.9 million. Interest income of $1.3 million partially offset operating losses.
The company ended the quarter with $132.3 million in cash, cash equivalents and marketable securities and an accumulated deficit of $378.9 million. Management believes this liquidity will fund currently planned operations into the second half of 2027 while it continues Phase 2 development of lead candidate PGN-EDODM1 for DM1.
PepGen Inc. (PEPG) reported Q3 results and strengthened liquidity following a September equity raise. The company ended September 30, 2025 with $163.7 million in cash, cash equivalents and marketable securities. Q3 net loss was $18.0 million (basic and diluted loss per share $0.52), driven by research and development expense of $13.4 million and general and administrative expense of $5.2 million.
In September 2025, PepGen completed an underwritten public offering, issuing 35,937,500 shares (including the underwriters’ option) for net proceeds of $107.6 million. With the improved cash position, management concluded that conditions raising substantial doubt about continuing as a going concern no longer exist and believes current resources will fund operations for at least 12 months; elsewhere the company indicates funding into the second half of 2027.
Clinical updates included PGN‑EDODM1 for DM1: the FREEDOM Phase 1 single‑dose study’s 15 mg/kg cohort showed a mean splicing correction of 53.7% and was generally well tolerated. Dose escalation will conclude at 15 mg/kg. The Phase 2 FREEDOM2 multiple‑dose study is open in Canada and the U.K., with initial 5 mg/kg cohort data expected in Q1 2026. Development of PGN‑EDO51 for DMD was discontinued in May 2025. Shares outstanding were 68,748,224 as of November 5, 2025.